Opinion

Video

HER2CLIMB-02 Trial: Exploring Tucatinib and T-DM1 for HER2+ mBC

Panelists discuss recent data from the HER2CLIMB-02 trial, highlighting the findings and their implications for treatment practices in HER2-positive breast cancer, particularly for patients with brain metastases.

Related Videos
5 experts are featured in this series
5 experts are featured in this series
Related Content